MANNKIND CORP Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.39M, a 46.06% increase year-over-year.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $951.00K, a 0.83% decline year-over-year.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $959.00K, a 3.90% increase year-over-year.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $923.00K.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.60M, a 9.73% decline from fiscal 2024.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.78M, a 6.59% increase from fiscal 2023.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.67M, a 19.88% decline from fiscal 2022.
- MANNKIND CORP stock issued during period, value, employee stock purchase plan for fiscal 2022 was $2.08M, a 91.01% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.39M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $1.60M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $951.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $1.78M 10-K · filed 2026-02-26 | |
| 2024-06-30 | $959.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $1.67M 10-K · filed 2026-02-26 | |
| 2023-06-30 | $923.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $2.08M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $873.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $740.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $1.09M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $700.00K 10-Q · filed 2021-11-09 | |
| 2021-03-31 | $390.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $684.00K 10-K · filed 2023-02-23 | |
| 2020-09-30 | $366.00K 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $318.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $656.00K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $339.00K 10-Q · filed 2020-11-04 | |
| 2019-03-31 | $317.00K 10-Q · filed 2020-11-04 | |
| 2018-12-31 | $345.00K 10-K · filed 2020-02-25 | |
| 2018-09-30 | $343.00K 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $1.00K 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $236.00K 10-K · filed 2019-02-26 | |
| 2016-12-31 | $426.00K 10-K · filed 2019-02-26 | |
| 2015-12-31 | $887.00K 10-K · filed 2018-02-27 | |
| 2014-12-31 | $1.36M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $1.26M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $862.00K 10-K · filed 2015-03-02 | |
| 2011-12-31 | $769.00K 10-K · filed 2014-03-03 | |
| 2010-12-31 | $1.60M 10-K · filed 2014-03-03 | |
| 2009-12-31 | $1.40M 10-K · filed 2014-03-03 | |
| 2008-12-31 | $900.00K 10-K · filed 2014-03-03 | |
| 2007-12-31 | $1.06M 10-K · filed 2014-03-03 | |
| 2006-12-31 | $981.00K 10-K · filed 2014-03-03 | |
| 2005-12-31 | $495.00K 10-K · filed 2014-03-03 | |
| 2004-12-31 | $430.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |